Paul McBarron
2022
In 2022, Paul McBarron earned a total compensation of $394.7K as Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary at Cyclacel Pharmaceuticals, a 44% decrease compared to previous year.
Compensation breakdown
| Bonus | $93,655 |
|---|---|
| Salary | $279,568 |
| Other | $21,452 |
| Total | $394,675 |
McBarron received $279.6K in salary, accounting for 71% of the total pay in 2022.
McBarron also received $93.7K in bonus and $21.5K in other compensation.
Rankings
In 2022, Paul McBarron's compensation ranked 4,700th out of 5,717 executives tracked by ExecPay. In other words, McBarron earned more than 17.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,700 out of 5,717 | 18th |
Division Manufacturing | 2,615 out of 3,111 | 16th |
Major group Chemicals And Allied Products | 1,235 out of 1,410 | 12th |
Industry group Drugs | 1,161 out of 1,311 | 11th |
Industry Pharmaceutical Preparations | 846 out of 957 | 12th |
Source: SEC filing on April 28, 2023.
McBarron's colleagues
We found two more compensation records of executives who worked with Paul McBarron at Cyclacel Pharmaceuticals in 2022.
News
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2023 pay slips 13% to $661K
May 7, 2024
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2022 pay falls 43% to $764K
April 28, 2023
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2021 pay slips 5% to $1.3M
April 26, 2022
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2020 pay jumps 39% to $1.4M
April 29, 2021
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2019 pay jumps 35% to $1M
May 12, 2020